Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4994663 | 0.86 | ESRRG (0.56) | EPHX2ALDH1A1MEN1KMT2A | |
| SCHEMBL4989136 | 0.84 | CYP3A4 (0.48) | MAPK14MAOBLTA4HEPHX2SCN9A | |
| SCHEMBL4985848 | 0.82 | OPRM1 (0.51) | MAPK14LTA4H | |
| SCHEMBL4994474 | 0.81 | MAPK14 (0.52) | MAPK14MAOBLTA4HEPHX2ALDH1A1 | |
| SCHEMBL7457448 | 0.81 | SRD5A2 (0.47) | MAOBALDH1A1MEN1KMT2APPARA | |
| SCHEMBL4995481 | 0.81 | CYP2C9 (0.56) | MAPK14LTA4HEPHX2ALDH1A1MEN1 | |
| SCHEMBL4992970 | 0.81 | PARP10 (0.51) | LTA4HALDH1A1 | |
| SCHEMBL7459589 | 0.80 | CARM1 (0.40) | MAPK14MAOBPPARASCN9A | |
| SCHEMBL4987260 | 0.79 | SLC1A3 (0.46) | MAOBPPARASCN9A | |
| SCHEMBL3691728 | 0.79 | MAOB (0.64) | MAPK14MAOBEPHX2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | claimed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | claimed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | claimed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | claimed |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | PURDUE PHARMA L.P. (US) | 2008-12-25 | — | — | US | disclosed |
| US-7393872-B2 | Sodium channel blocker compositions and the use thereof | EURO-CELTIQUE S.A. (LU) | 2008-07-01 | — | — | US | disclosed |
| EP-1169060-B1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2005-08-31 | — | — | EP | disclosed |
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA L.P. | 2004-03-18 | — | — | US | disclosed |
| EP-1058550-A4 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | PURDUE PHARMA LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2000061188-A9 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169060-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-09 | — | — | EP | disclosed |
| US-6281211-B1 | TREATING A DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2001-08-28 | — | — | US | disclosed |
| EP-1058550-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000061188-A1 | SODIUM CHANNEL BLOCKER COMPOSITIONS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-19 | — | — | WO | disclosed |
| WO-1999039712-A9 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | COCENSYS INC (US) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999039712-A1 | SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF | EURO-CELTIQUE S.A. (BE) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054005-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | MAPK14 4016/4885MAOB 565/4885LTA4H 559/4885 |
| US-20080318932-A1 | Sodium Channel Blocker Compositions and the Use Thereof | CACNA1B, CACNB2, CACNA1C | MAPK14 4016/4885MAOB 565/4885LTA4H 559/4885 |
| US-20020037926-A1 | Sodium channel blocker compositions and the use thereof | CACNA1B, CACNB2, CACNA1C | MAPK14 4016/4885MAOB 565/4885LTA4H 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.